Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PTIE's Cash to Debt is ranked higher than
95% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. PTIE: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PTIE' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
94% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTIE' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 20.27
M-Score: -4.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -39.99
PTIE's ROE (%) is ranked lower than
56% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. PTIE: -39.99 )
Ranked among companies with meaningful ROE (%) only.
PTIE' s ROE (%) Range Over the Past 10 Years
Min: -40.75  Med: -5.01 Max: 102.69
Current: -39.99
-40.75
102.69
ROA (%) -38.05
PTIE's ROA (%) is ranked lower than
61% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. PTIE: -38.05 )
Ranked among companies with meaningful ROA (%) only.
PTIE' s ROA (%) Range Over the Past 10 Years
Min: -38.85  Med: -2.25 Max: 58.98
Current: -38.05
-38.85
58.98
ROC (Joel Greenblatt) (%) -7058.65
PTIE's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. PTIE: -7058.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTIE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -38255.38  Med: -1726.78 Max: 731.79
Current: -7058.65
-38255.38
731.79
Revenue Growth (3Y)(%) -100.00
PTIE's Revenue Growth (3Y)(%) is ranked lower than
95% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PTIE: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTIE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 132.2
Current: -100
0
132.2
EBITDA Growth (3Y)(%) 54.40
PTIE's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. PTIE: 54.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTIE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.3  Med: 18.20 Max: 54.4
Current: 54.4
-18.3
54.4
EPS Growth (3Y)(%) 58.90
PTIE's EPS Growth (3Y)(%) is ranked higher than
93% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PTIE: 58.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTIE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.9  Med: 5.90 Max: 66.8
Current: 58.9
-31.9
66.8
» PTIE's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PTIE Guru Trades in Q1 2015

Jim Simons 338,687 sh (+11.27%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 70,000 sh (-17.65%)
» More
Q2 2015

PTIE Guru Trades in Q2 2015

George Soros 21,700 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 519,687 sh (+53.44%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 65,000 sh (-7.14%)
» More
Q3 2015

PTIE Guru Trades in Q3 2015

Charles Brandes 18,937 sh (New)
Jim Simons 596,387 sh (+14.76%)
Mario Gabelli 65,000 sh (unchged)
First Eagle Investment 5,684,510 sh (unchged)
Louis Moore Bacon Sold Out
George Soros Sold Out
» More
Q4 2015

PTIE Guru Trades in Q4 2015

Jim Simons 672,787 sh (+12.81%)
First Eagle Investment 5,684,510 sh (unchged)
Mario Gabelli 65,000 sh (unchged)
Charles Brandes 18,141 sh (-4.20%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.78
PTIE's P/B is ranked lower than
54% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. PTIE: 3.78 )
Ranked among companies with meaningful P/B only.
PTIE' s P/B Range Over the Past 10 Years
Min: 1.55  Med: 3.96 Max: 15.24
Current: 3.78
1.55
15.24
Shiller P/E 33.84
PTIE's Shiller P/E is ranked higher than
75% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.88 vs. PTIE: 33.84 )
Ranked among companies with meaningful Shiller P/E only.
PTIE' s Shiller P/E Range Over the Past 10 Years
Min: 21.99  Med: 59.13 Max: 451
Current: 33.84
21.99
451
Current Ratio 12.42
PTIE's Current Ratio is ranked higher than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. PTIE: 12.42 )
Ranked among companies with meaningful Current Ratio only.
PTIE' s Current Ratio Range Over the Past 10 Years
Min: 5.65  Med: 12.42 Max: 48.03
Current: 12.42
5.65
48.03
Quick Ratio 12.42
PTIE's Quick Ratio is ranked higher than
81% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PTIE: 12.42 )
Ranked among companies with meaningful Quick Ratio only.
PTIE' s Quick Ratio Range Over the Past 10 Years
Min: 5.65  Med: 12.42 Max: 48.03
Current: 12.42
5.65
48.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.84
PTIE's Price/Net Cash is ranked higher than
65% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. PTIE: 3.84 )
Ranked among companies with meaningful Price/Net Cash only.
PTIE' s Price/Net Cash Range Over the Past 10 Years
Min: 1.38  Med: 4.25 Max: 30.22
Current: 3.84
1.38
30.22
Price/Net Current Asset Value 3.78
PTIE's Price/Net Current Asset Value is ranked higher than
65% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. PTIE: 3.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTIE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.35  Med: 3.89 Max: 9.68
Current: 3.78
1.35
9.68
Price/Tangible Book 3.78
PTIE's Price/Tangible Book is ranked higher than
55% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. PTIE: 3.78 )
Ranked among companies with meaningful Price/Tangible Book only.
PTIE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.29  Med: 3.79 Max: 9.34
Current: 3.78
1.29
9.34
Price/Projected FCF 6.54
PTIE's Price/Projected FCF is ranked lower than
66% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. PTIE: 6.54 )
Ranked among companies with meaningful Price/Projected FCF only.
PTIE' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.08  Med: 2.60 Max: 9.34
Current: 6.54
1.08
9.34
Earnings Yield (Greenblatt) (%) -17.92
PTIE's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. PTIE: -17.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTIE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -17.92  Med: 15.50 Max: 754.5
Current: -17.92
-17.92
754.5

More Statistics

Revenue(Mil) $41
EPS $ -0.31
Beta1.62
Short Percentage of Float1.50%
52-Week Range $1.53 - 3.65
Shares Outstanding(Mil)45.76

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -0.70 -0.90 -0.50
EPS without NRI($) -0.70 -0.90 -0.50

Business Description

Industry: Biotechnology » Biotechnology
Compare:ASX:NEU, OSTO:PROB, AMEX:OCX, NAS:PSTI, LSE:RENE, NAS:CDXS » details
Traded in other countries:PX9.Germany,
Pain Therapeutics Inc a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It believes this focus will enable the company to generate product revenues earlier than if it was focused on early-stage research and discovery activities; Retain Significant Rights to Drugs: It currently retain worldwide commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Pain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review Apr 13 2016
DURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016 Apr 12 2016
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 Apr 12 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 12 2016
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 Apr 12 2016
DRRX: REMOXY® NDA Resubmitted Mar 30 2016
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug... Mar 29 2016
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration Mar 29 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 29 2016
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration Mar 29 2016
Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids Mar 15 2016
PAIN THERAPEUTICS INC Financials Mar 10 2016
PAIN THERAPEUTICS INC Files SEC form 10-K, Annual Report Mar 03 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2016
Pain Therapeutics Reports 2015 Financial Results and Corporate Update Mar 01 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 22 2015
Equities Driven By Market Influences - Research on Huttig Building Products, Pain Therapeutics,... Dec 02 2015
Hedge Funds Are Abandoing Pain Therapeutics, Inc. (PTIE) Nov 24 2015
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 10 2015
PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Nov 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK